StockNews.com began coverage on shares of iCAD (NASDAQ:ICAD - Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the technology company's stock.
Other analysts have also recently issued reports about the company. Craig Hallum cut iCAD from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Laidlaw reissued a "hold" rating on shares of iCAD in a report on Thursday, April 17th. Finally, BTIG Research lowered shares of iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th.
Check Out Our Latest Report on ICAD
iCAD Trading Down 0.5%
ICAD stock traded down $0.02 during midday trading on Monday, reaching $3.91. The company had a trading volume of 409,846 shares, compared to its average volume of 401,473. iCAD has a 1 year low of $1.18 and a 1 year high of $4.00. The company has a market capitalization of $107.31 million, a P/E ratio of -30.08 and a beta of 1.35. The company has a 50 day moving average of $2.58 and a two-hundred day moving average of $2.35.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The firm had revenue of $4.87 million during the quarter, compared to analysts' expectations of $4.54 million.
Institutional Investors Weigh In On iCAD
Hedge funds have recently bought and sold shares of the stock. Summit Trail Advisors LLC acquired a new stake in iCAD during the fourth quarter worth approximately $214,000. Geode Capital Management LLC grew its holdings in iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in iCAD by 6.1% in the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock valued at $1,311,000 after buying an additional 41,000 shares in the last quarter. Wells Fargo & Company MN grew its holdings in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after buying an additional 13,402 shares in the last quarter. Finally, Granahan Investment Management LLC acquired a new position in iCAD in the 4th quarter valued at $96,000. 24.61% of the stock is currently owned by institutional investors and hedge funds.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Further Reading
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
